Ask AI
BsAbs in Multiple Myeloma

CME

Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Roundtable of Considerations and Strategies for Implementation Into Clinical Practice

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 15, 2025

Expiration: April 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In your discussion with a patient and his wife, which of the following bispecific antibodies would you tell them allows for biweekly dosing immediately after completing step-up dosing?

2.

Which of the following adverse events occurs more frequently with GPRC5D-targeted therapy compared with BCMA-targeted therapy in multiple myeloma?

3.

You are treating a patient with teclistamab who completed step-up dosing and is on cycle 6 of standard dosing. The patient presents with a new fever and general fatigue. What potential cause do you suspect?

4.

A 76-year-old man with an 8-year history of triple-class refractory multiple myeloma (previous treatments include an immunomodulatory drug, proteasome inhibitor, and anti-CD38 mAb) and comorbidities of coronary artery disease, hypertension, and diabetes mellitus has started talquetamab and is admitted for inpatient monitoring. Seventeen hours after his first full treatment dose, he develops symptoms consistent with grade 2 CRS.

According to the prescribing information and the CRS management strategy outlined in the MonumenTAL-1 protocol, how should this patient be managed?